Aarti Industries Share: Pros and Cons Every Investor Must Know in 2026

Aarti Industries share CMP approx Rs 509. 52-week high Rs 650, low Rs 430. Market Cap Rs 18,140 Cr. P/E ratio 34.16x.

Is the Aarti Industries share a good investment in 2026? This article provides a data-driven analysis of Aarti Industries share pros and cons — covering business strengths, valuation, growth drivers, and key risks — based on live data from 7 August 2026.

Click Here — Get Free Investment Predictions

About Aarti Industries

Aarti Industries Limited (NSE: AARTIIND) is a Vapi-based specialty chemicals company founded in 1975. India’s largest benzene-based specialty chemical manufacturer, it produces 1,000-plus chemical products including nitrobenzene, chlorobenzene, sulphuric acid derivatives, and downstream specialty chemicals for agrochemical, pharmaceutical, polymer, and FMCG industries globally. Aarti Industries serves 700-plus global chemical companies across 60 countries.

Key Financial Snapshot: Aarti Industries Share

Data approximate. Verify at nseindia.com.

Top 5 Pros of Aarti Industries Share

1. India’s Largest Benzene Specialty Chemical Chain — Diversified 1,000-Plus Product Portfolio

Aarti Industries share represents India’s most comprehensive benzene chemistry value chain — from basic aromatic chemistry to specialty downstream products for agro, pharma, polymer, and FMCG industries. This diversified 1,000-plus product portfolio reduces exposure to any single product’s demand cycle.

2. Long-Term CRAMS-Like Pharma Specialty Contracts — Sticky Client Relationships

Aarti Industries serves global specialty chemical and pharmaceutical companies with long-term supply agreements for specific intermediates. These contracts provide multi-year revenue visibility and create high switching costs for clients who have qualified Aarti’s specific synthesis processes in their regulated manufacturing.

3. India’s China-Plus-One Specialty Chemical Beneficiary — Supply Chain Diversification

Global chemical companies seeking to diversify away from Chinese specialty chemical dependency are increasingly qualifying Indian suppliers like Aarti Industries. As India’s China-plus-one chemical sourcing grows, Aarti’s diversified product range and scale position it as a preferred Indian specialty chemical alternative.

4. Export Revenue From 60 Countries — Geographic Revenue Diversification

Aarti Industries exports to 60-plus countries, providing revenue diversification across global chemical demand cycles. This geographic diversity reduces India-domestic cycle dependency and provides USD revenue that benefits during INR depreciation.

5. Pharma Specialty Demerger — Aarti Pharmalabs Creating Focused Pharma Chemistry Entity

Aarti Industries demerged its pharmaceutical chemicals business as Aarti Pharmalabs Limited, creating a focused specialty pharma chemistry entity. This demerger aims to unlock value by allowing pharma-focused investors to value the pharma chemistry business independently at pharmaceutical company multiples.

Key Cons of Aarti Industries Share

1. ROE of 7.04 Percent Very Low — Transition Year From Demerger and Capacity Expansion

At 7.04% ROE with debt-to-equity of 0.83x, Aarti Industries share is significantly below quality specialty chemical benchmarks. The low ROE reflects the transition year after the Aarti Pharmalabs demerger (removing high-margin pharma chemistry from the parent) and new capacity investment that has increased capital employed without proportional revenue yet.

2. Aarti Pharmalabs Demerger Impact — Parent’s Revenue and Margins Reduced

The demerger of Aarti Pharmalabs removed the high-margin pharma chemistry business from Aarti Industries’ revenue. The parent company’s remaining benzene specialty portfolio has lower margins than the pharma chemistry business, compressing overall ROE and PE attractiveness temporarily.

3. Chinese Specialty Chemical Competition — Aarti Faces Price Pressure in Benzene Derivatives

Benzene-based specialty chemicals are a category where China has significant production scale. Chinese chlorobenzene and nitrobenzene manufacturers can undercut Aarti’s prices in standard-grade products, limiting Aarti’s ability to raise prices in the commodity chemistry segment of its portfolio.

4. 34.16x PE Elevated for 7.04 Percent ROE — Transition Year Multiple Distortion

At 34.16x PE with only 7.04% ROE, Aarti Industries share is expensive relative to current earnings quality. The investment thesis requires ROE to recover above 12 percent as transition effects normalise and new capacity generates full utilisation revenue.

Use the Univest Screener to Analyse Stocks for Free

Is Aarti Industries Share a Good Investment in 2026?

Aarti Industries share requires ROE recovery from current 7.04% levels before the 34.16x PE is comfortable. The China-plus-one tailwind and long-term specialty chemical contracts are genuine positives. Consider after ROE recovery evidence above 12 percent.

Key Risks Before Buying Aarti Industries Share

• Aarti Pharmalabs demerger taking longer to stabilise than expected keeping parent ROE suppressed
• Chinese specialty chemical dumping in benzene derivatives further compressing Aarti’s margins
• New chemical capacity utilisation ramp-up slower than guided extending the transition period
• Global agrochemical and polymer demand slowdown reducing specialty chemical order volumes

Conclusion

The Aarti Industries share offers india’s largest benzene specialty chemical chain — diversified 1,000-plus product portfolio as its primary investment case. Weigh it against roe of 7.04 percent very low — transition year from demerger and capacity expansion and the risks above before investing. Use the Univest Screener and consult a SEBI-registered advisor.

Download the Univest iOS App or Univest Android App to track Aarti Industries share price live.

Frequently Asked Questions — Aarti Industries Share

What are the main pros of Aarti Industries share?

Ans. India’s largest benzene specialty chemical chain with 1,000-plus diversified products, long-term CRAMS-like pharma specialty contracts with sticky client relationships, India’s China-plus-one beneficiary for specialty chemical supply diversification, 60-country export revenue diversification, and Aarti Pharmalabs demerger potentially unlocking value.

What are the risks of Aarti Industries share?

Ans. ROE of 7.04% very low from demerger and capacity expansion transition, Aarti Pharmalabs demerger removing high-margin pharma chemistry from parent, Chinese benzene derivative price competition, and 34.16x PE elevated for current ROE requiring recovery above 12%. Wait for ROE improvement evidence.

Is Aarti Industries share a good investment?

Ans. Consider after ROE recovery above 12% from transition normalisation. Currently transition-year. Consult a SEBI-registered advisor. Not investment advice.

What is the 52-week range of Aarti Industries share?

Ans. 52-week high approximately Rs 650, low Rs 430. Verify at nseindia.com.

What was the Aarti Pharmalabs demerger?

Ans. Aarti Industries demerged its pharmaceutical specialty chemical business — manufacturing pharmaceutical intermediates, APIs, and specialty pharma chemicals for global drug companies — as Aarti Pharmalabs Limited (separately listed). The rationale was that pharma chemistry commands higher valuation multiples (40 to 60x PE) than commodity benzene derivatives (15 to 25x PE). By creating a focused pharma entity, Aarti aimed to let each business be valued at its own appropriate sector multiple rather than the blended conglomerate discount.

What does Aarti Industries produce?

Ans. Aarti Industries produces across categories: Benzene-based aromatics (chlorobenzene, nitrobenzene, aniline), Sulphuric acid derivatives (oleum, chloro-sulphuric acid), Hydrogenation products (cyclohexylamine, dicyclohexylamine), Polymer intermediates (ABS precursors, specialty monomers), Agrochemical intermediates (herbicide, fungicide building blocks), and Performance chemicals for FMCG, personal care, and textile processing. Each category serves different downstream industry verticals across India and 60 export countries.